Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Niveditha Nerlakanti"'
Autor:
Ryan T. Bishop, Anna K. Miller, Matthew Froid, Niveditha Nerlakanti, Tao Li, Jeremy S. Frieling, Mostafa M. Nasr, Karl J. Nyman, Praneeth R. Sudalagunta, Rafael R. Canevarolo, Ariosto Siqueira Silva, Kenneth H. Shain, Conor C. Lynch, David Basanta
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is ch
Externí odkaz:
https://doaj.org/article/6a891d57aa954ccea72f58bdbad908a5
Autor:
Ryan T. Bishop, Tao Li, Raghunandan R. Alugubelli, Mostafa Nasr, Karl J. Nyman, Praneeth Sudalagunta, Mark Meads, Jeremy Frieling, Niveditha Nerlakanti, Marilena Tauro, Oliver Hampton, Bin Fang, Steven Grant, John Koomen, Ariosto Siqueira Silva, Kenneth H. Shain, Conor C. Lynch
Publikováno v:
Journal of Bone Oncology, Vol 45, Iss , Pp 100539- (2024)
Externí odkaz:
https://doaj.org/article/521fc9dd9d7d46f098490ae18ec77b15
Autor:
Kiran Mahajan, Ernst Schonbrunn, Nicholas J. Lawrence, Ranjan Perera, Youngchul Kim, Uwe Rix, Subramaniam Shymalagovindarajan, Jingsong Zhang, Jasreman Dhillon, Domenico Coppola, Anthony M. Magliocco, John Puskas, Norbert Berndt, Rezaul M. Karim, Steven Gunawan, Yunyun Chen, Neha Agarwal, Brent M. Kuenzi, Muhammad Ayaz, Harshani R. Lawrence, Alexey M. Eroshkin, Ami K. Patel, Duy T. Nguyen, Jiqiang Yao, Niveditha Nerlakanti
Supplementary Fig. 1. Epigenetic landscape and the transcription cofactor recruitment at the HOXB13 enhancer region under various treatments; Supplementary Figure 2. BRD4 is a target of the dual BET-kinase inhibitors in CRPCs; Supplementary Figure 3.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba9532fee211fdd48d8b5145a41ce0a4
https://doi.org/10.1158/1535-7163.22504905.v1
https://doi.org/10.1158/1535-7163.22504905.v1
Autor:
Kiran Mahajan, Ernst Schonbrunn, Nicholas J. Lawrence, Ranjan Perera, Youngchul Kim, Uwe Rix, Subramaniam Shymalagovindarajan, Jingsong Zhang, Jasreman Dhillon, Domenico Coppola, Anthony M. Magliocco, John Puskas, Norbert Berndt, Rezaul M. Karim, Steven Gunawan, Yunyun Chen, Neha Agarwal, Brent M. Kuenzi, Muhammad Ayaz, Harshani R. Lawrence, Alexey M. Eroshkin, Ami K. Patel, Duy T. Nguyen, Jiqiang Yao, Niveditha Nerlakanti
Supplementary Table 1: Table provides information on the siRNA sequences and/or chemical structures of the non-FDA approved inhibitors for bromodomain proteins, transcription factors and kinases described in the current study. Supplementary Table 2:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ce2b2dd01ae32a0980a741719a0d9f3
https://doi.org/10.1158/1535-7163.22504902.v1
https://doi.org/10.1158/1535-7163.22504902.v1
Autor:
Anna K. Miller, Ryan T. Bishop, Tao Li, Kenneth H. Shain, Niveditha Nerlakanti, Conor C. Lynch, David Basanta
Multiple myeloma (MM) is an osteolytic plasma cell malignancy that, despite being responsive to therapies such as proteasome inhibitors, frequently relapses. Understanding the mechanism and the niches where resistant disease evolves remains of major
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79697c6e61b3867c290144963574d250
https://doi.org/10.1101/2022.11.13.516335
https://doi.org/10.1101/2022.11.13.516335
Autor:
Niveditha Nerlakanti, Jeremy McGuire, Ryan T. Bishop, Diana Yu, Damon R. Reed, Conor C. Lynch
Publikováno v:
Cancer Research. 83:276-276
Osteosarcoma (OS) frequently metastasizes to lung where it greatly contributes to patient mortality. Frustratingly, OS treatment options have remained static due to a paucity of strong pre-clinical evidence to motivate clinical trials. To identify th
Autor:
Alexey Eroshkin, Ami Patel, Young-Chul Kim, Neha Agarwal, Duy T. Nguyen, Domenico Coppola, Niveditha Nerlakanti, Ranjan J. Perera, Jingsong Zhang, Jiqiang Yao, Zachary J. Thompson, Jamie K. Teer, Jasreman Dhillon, Yunyun Chen, Kiran Mahajan
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-18 (2019)
Scientific Reports
Scientific Reports
HOXB13, a homeodomain transcription factor, is linked to recurrence following radical prostatectomy. While HOXB13 regulates Androgen Receptor (AR) functions in a context dependent manner, its critical effectors in prostate cancer (PC) metastasis rema
Publikováno v:
Cancer Research. 82:988-988
Background: Osteosarcoma (OS) frequently metastasizes to lung and the prognosis for these patients is grim with 5-year overall survival rates as low as 30%. There has been little change in the treatment paradigm for this disease and new targeted ther
Autor:
Youngchul Kim, Kiran Mahajan, Jasreman Dhillon, Jingsong Zhang, Steven Gunawan, Norbert Berndt, Domenico Coppola, Neha Agarwal, Rezaul M. Karim, Niveditha Nerlakanti, Alexey Eroshkin, Ernst Schönbrunn, Brent M. Kuenzi, Duy T. Nguyen, John Puskas, Yunyun Chen, Anthony M. Magliocco, Muhammad Ayaz, Jiqiang Yao, Nicholas J. Lawrence, Harshani R. Lawrence, Uwe Rix, Ami Patel, Ranjan J. Perera, Subramaniam Shymalagovindarajan
Publikováno v:
Molecular Cancer Therapeutics. 17:2796-2810
Resistance to androgen receptor (AR) antagonists is a significant problem in the treatment of castration-resistant prostate cancers (CRPC). Identification of the mechanisms by which CRPCs evade androgen deprivation therapies (ADT) is critical to deve
Autor:
Niveditha Nerlakanti, Karen L. Burger, Paul A. Stewart, John L. Cleveland, Jeremy S. Frieling, Jeremy J. McGuire, Leah M. Cook, Conor C. Lynch
Publikováno v:
Oncogene. 38(44)
Bone metastatic prostate cancer provokes extensive osteogenesis by driving the recruitment and osteoblastic differentiation of mesenchymal stromal cells (MSCs). The resulting lesions greatly contribute to patient morbidity and mortality, underscoring